一种成功的药物类别并不保证一种成功的方案。将纳武利尤单抗添加到围手术期GC未能改善EFS。阴性试验很重要。
@Annals_Oncology @tompowles1
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26
464 浏览 · 6 赞 · 6 转发 · 1 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org📢 #ESMO26 concomitant paper - Neoadjuvant nivolumab + gem/cis followed by postsurgical adjuvant nivolumab vs neoadjuvant gem/cis in pts with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial. 🔗https://shorturl.at/XxETb @sonpavde @AndreaNecchi在 X 查看被引用的帖子
- Michiel Strijbos@StrijbosMichiel
@DrYukselUrun @Annals_Oncology @tompowles1 @myESMO @OncoAlert @OpenMedicineHQ A triumphant drug class is no golden ticket. Nivolumab + perioperative GC left EFS unchanged—a quiet reminder that even stars can fail to shine in every constellation. Negative trials still light the way. ✨
来源：Yüksel Ürün · x.com